Abstract
Background. Clostridioides (Clostridium) difficile colonization is common among infants. Serological sequelae of infant C. difficile colonization are poorly understood. Methods. In this prospective cohort study of healthy infants, stools serially collected between ages 1-2 and 9-12 months were tested for non-toxigenic and toxigenic C. difficile (TCD). Cultured isolates underwent whole-genome sequencing. Serum collected at 9-12 months underwent measurement of IgA, IgG, and IgM against TCD toxins A and B and neutralizing antibody (NAb) titers against toxin B. For comparison, antitoxin IgG and NAb were measured in cord blood from 50 mothers unrelated to study infants. Results. Among 32 infants, 16 (50%) were colonized with TCD; 12 were first colonized >1 month before serology measurements. A variety of sequence types were identified, and there was evidence of putative in-home (enrolled siblings) and outpatient clinic transmission. Infants first colonized with TCD >1 month prior had significantly greater serum antitoxin IgA and IgG against toxins A (P =.02 for both) and B (P =.009 and.008, respectively) compared with non-TCD-colonized infants, and greater IgG compared with unrelated cord blood (P =.005). Five of 12 (42%) colonized infants had detectable NAb titers compared with zero non-TCD-colonized infants (P =.02). Breastfeeding was not associated with differences in serological measurements. Conclusions. TCD colonization is associated with a humoral immune response against toxins A and B, with evidence of toxin B neutralization in vitro. The extent and duration of protection against CDI later in life afforded by natural C. difficile immunization events require further investigation.
Original language | English (US) |
---|---|
Pages (from-to) | 2095-2102 |
Number of pages | 8 |
Journal | Clinical Infectious Diseases |
Volume | 70 |
Issue number | 10 |
DOIs | |
State | Published - May 6 2020 |
Funding
Financial support. This work was supported by grants from Lurie Children’s Hospital (Pediatric Physician-Scientist Research Career Development Award to L. K. K.), the Gerber Foundation (Novice Researcher Award to L. K. K.), the American Cancer Society (grant number MRSG-13-220-01 to E. A. O.), the National Institute of Allergy and Infectious Diseases (grant numbers K23 AI123525 to L. K. K., K24 AI104831 to A. R. H., U01 AI24290 to T. S. and M. E. C., and R01 AI116596, U19 AI109776, and R01 AI132711 to C. P. K.), and the National Institute of Diabetes and Digestive and Kidney Diseases (grant number P30 DK56338 to T. S.) at the National Institutes of Health. Research reported in this publication was supported, in part, by the National Institutes of Health’s National Center for Advancing Translational Sciences, grant number UL1TR001422.
Keywords
- C. difficile
- Immunity
- Pediatric
- Prevention
- Toxin
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases